Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Survey Reveals Large Number of Prion Carriers in the United Kingdom

By LabMedica International staff writers
Posted on 28 Oct 2013
A second immunohistochemistry survey of archived appendix samples conducted in the United Kingdom has found that the number of individuals carrying variant Creutzfeldt-Jakob disease prions was more than double that found in the first survey.

Variant Creutzfeldt-Jakob disease (vCJD) is a prion disease that was first described in 1996 in the United Kingdom. More...
Scientific evidence has shown that the agent responsible for the outbreak of prion disease in cows, bovine spongiform encephalopathy (BSE or "mad cow” disease), is the same agent responsible for the outbreak of vCJD in humans. Both disorders are invariably fatal brain diseases with unusually long incubation periods measured in years, and are caused by an unconventional transmissible agent called a prion. vCJD is not the same disease as classic CJD, which has different clinical and pathologic characteristics.

Although there have been only 177 clinical cases of vCJD to date in the United Kingdom, previous studies have estimated that around one in 4,000 people may carry vCJD prions. To confirm this estimate, investigators at the Institute of Neurology of University College London (United Kingdom) tested 32,441 archived appendix samples fixed in formalin and embedded in paraffin (FFPE) for the presence of abnormal prion protein (PrP).

They identified 16 appendix samples positive for abnormal PrP, indicating an overall prevalence of 493 per million. From this figure, the investigators estimated that one in 2,000 people were likely to be carriers.

The prevalence of the prion in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.

Genetic testing of the 16 positive samples revealed a higher proportion of the valine homozygous (VV) genotype on the codon 129 of the gene encoding the prion protein (PRNP) compared with the general population of the United Kingdom. This genotype also differed from the 177 patients with vCJD, all of whom displayed the methionine homozygous (MM) genotype.

The investigators concluded that, "This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date. These findings have important implications for the management of blood and blood products and for the handling of surgical instruments."

The study was published in the October 15, 2013, online edition of the British Medical Journal.

Related Links:

University College London




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.